Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

US: ACLU, PUBPAT and others file lawsuit challenging constitutionality of patents on human genes associated with breast and ovarian cancer: Association for Molecular Pathology et al v USPTO et al (Patent Baristas) (Ars Technica) (Patently-O) (IP Watchdog) (The Prior Art) (Patent Docs) (Patents4Life)

Omnicef (Cefdinir) – US: CAFC rules en banc: Terms in product-by-process claims are limitations in determining infringement: Abbott Laboratories v Sandoz (Peter Zura’s 271 Patent Blog) (Patent Docs) (Inventive Step) (Patently-O)

IP Think Tank podcast: Biotech IP at the crossroads (IP Think Tank) (PatentlyBIOtech)

WHO meeting on pandemic flu reconvenes under pressure, IP laws key point of contention; fails to finish pandemic flu preparations (Intellectual Property Watch) (Intellectual Property Watch)

World Health Assembly takes on R&D, pandemics, not counterfeits; pandemic flu a top focus but IP issues unresolved (Intellectual Property Watch) (Intellectual Property Watch)

Experts aim to balance IP rights and human rights (Intellectual Property Watch)

Scientific American Worldview: measuring global biotechnology innovation (BiotechBlog)

Creative destruction in biotechnology (Biotech Blog)

Africa pharmaceuticals trademark network? (Afro-IP)

Brazil: Counterfeit and parallel importation of medicines affect confidence of Brazilians: Call for stringent action from the government (IP tango)

Brazil: Pipeline patents in Brazil: constitutional, or not? (IP tango)

China: China IP forum to bring third patent amendment face-to-face with biotechnology concerns (PatentlyBIOtech)

France: Patent and SPC status searches on the INPI website (The SPC Blog)

India: Government republishes controversial report on patentability of pharmaceuticals and microorganisms (Managing Intellectual Property)

India: The pharmaceutical patent debate: wither drug safety?: Dr Reddy’s post grant opposition against Pfizer’s Champix patent (Spicy IP)

Tanzania generic pharma sector set for growth (Afro-IP)

US: ACLU, PUBPAT and others file lawsuit challenging constitutionality of patents on human genes associated with breast and ovarian cancer: Association for Molecular Pathology et al v USPTO et al (Patent Baristas) (Ars Technica) (Patently-O) (IP Watchdog) (The Prior Art) (Patent Docs) (Patents4Life)

US: Obvious-type double patenting and splitting ownership (CAFC says don’t do it): In re Fallaux (Patently-O)

US: Monsanto files suit against E I Dupont De Nemours alleging stacked soybean product infringes Roundup Ready technology (Patent Docs)

US: FTC position on reverse payments: Settlements can be precompetitive (Patent Baristas)

US: BIO IP policy briefing (Patent Docs)

US: Why blog about intellectual property? BIO Policy Briefing raises the IP social media question (PatentlyBIOtech)

Vietnam: Patentability of medical use claims in Vietnam (RelatIP)

Actonel (Risedronic) – US: CAFC affirms Procter & Gamble’s Actonel patent validity; nonobviousness of positional isomer: Procter & Gamble v Teva (Patent Docs) (Patently-O) (SmartBrief) (SmartBrief) (GenericsWeb)

Alimta (Pemetrexed) – US: Eli Lilly and Princeton University sue Barr alleging infringement of Alimta patent (Technology Transfer Tactics)

Allicin – US: Yeda files suit seeking review and correction of patent term adjustment calculation for patent covering ‘site-specific in sit generation of Allicin using targeted alliinase delivery system..’ (Patent Docs)

Atripla/Truvada (Efavirenz, Emtricitabine, Tenofovir) – US: Gilead Sciences files second patent infringement lawsuit against Teva Pharmaceuticals over Emtricitabine, a component of Truvada and Atripla (SmartBrief) (The IP Factor) (GenericsWeb)

Champix (Varenicline) – India: Pfizer responds to Dr Reddy’s post-grant opposition to Champix filed at Mumbai Patent Office (GenericsWeb) (Spicy IP)

Corpril (Ramipril) – Hungary: Metropolitan Board of Appeal rules human cosmetics and veterinary products dissimilar in opposition by Lidl to Ranbaxy’s CORPRIL for pharmaceutical products for human and veterinary use (Class 46)

Dovonex (Calcipotriol) – UK: Patent Court of England and Wales: Leo’s patent valid and infringed; Floyd J comments on lack of supra-national patent court: Leo Pharma v Sandoz (PatLit)

Effexor (Venlafaxine) – US: Wyeth, Lupin settle Effexor patent dispute (Patent Circle) (GenericsWeb)

Levaquin (Levofloxacin) / Floxin (Ofloxacin)  US: District Court New Jersey affirms enantiomer PTE validity; decision quickly appealed to the Federal Circuit: Stereoisomer orphan drug ‘sameness’ – another interesting counterpoint to FDA’s first permitted commercial marketing or use PTE determinations: Ortho-McNeil Pharmaceutical et al v Lupin Pharmaceutical et al (FDA Law Blog) (FDA Law Blog)

Lyrica (Pregabalin) – US: Pfizer, Warner-Lambert and CP Pharmaceuticals file patent infringement suit against Mylan and Alphapharm in attempt to block generic Lyrica (GenericsWeb)

Mucinex (Guaifenesin, Pseudoephedrine) – US: Reckitt Benckiser sues Watson for patent infringement in response to generic Mucinex ANDA (GenericsWeb)

Omnicef (Cefdinir) – US: CAFC rules en banc: Terms in product-by-process claims are limitations in determining infringement: Abbott Laboratories v Sandoz (Peter Zura’s 271 Patent Blog) (Patent Docs) (Inventive Step) (Patently-O)

Pegasys (Peginterferon alfa-2a) – India: Roche defeats post-grant oppositions by Wockhardt and Sankalp to secure patent for Pegasys (International Law Office)

Protonix (Pantoprazole) – US: CAFC finds generic entry does not cause irreparable harm, affirms denial of preliminary injunction: Altana Pharma & Wyeth v Teva (Patently-O) (SmartBrief) (Patent Docs) (GenericsWeb)

Renvela (Sevelamer) – US: Genzyme sues Lupin for violation of Renvela patent (GenericsWeb)

Simponi (Golimumab) – US: Abbott Biotechnology files patent infringement suit against Centocor Ortho Biotech based on Centocor’s imminent launch of Simponi (Patent Docs)

Tarceva (Erlotinib) – India/US: More problems for Tarceva: Delhi High Court concludes polymorphic erlotinib hydrochloride not protected by compound patent; USFDA announces black box warning for Tarceva (Patent Circle)